News 22.06.2021 Schlieren (Zurich), Switzerland, 22, 2021 – Kuros Biosciences (SIX: KURN) today announced the publication of new data in eCM Journal, a peer-reviewed publication focusing on preclinical re-search in the musculoskeletal field, on the mechanism of action of its MagnetOs bone graft. The paper describes how immunomodulation by bone grafts with submicron...
News 16.06.2021 Zurich-Schlieren, Switzerland, June 16, 2021. Molecular Partners AG (SIX: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin® therapeutics, today announced the pricing of its initial public offering in the United States of 3,000,000 American Depositary Shares ("ADSs") at a public offering price...
News 14.06.2021 Zurich-Schlieren, Switzerland, June 13, 2021. Molecular Partners AG (SIX: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin® therapeutics, today announced that the first patient has been dosed in a new Phase 3 sub-study evaluating ensovibep, as part of the National Institutes of...
News 09.06.2021 Zurich-Schlieren, Switzerland, June 9, 2021. Molecular Partners AG (SIX: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin® therapeutics, today announced that it has commenced an initial public offering in the United States of 3,000,000 American Depositary Shares ("ADSs") pursuant to a registration...
Events, Internal events
Event date: 17.06.2021
Date: 17th June 2021 (9am or 7pm CET)
Abstract:
A critical consideration in biopharmaceutical development labs is the overarching integration of bioreactors, novel sensor technologies and state-of-the art reference analyzers with the ultimate goal of smarter process control. In a real lab-environment in Tokyo, we demonstrated the effective use of the Lucullus...